Search Page

1

Cite

Share

Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.

Hofheinz RD, Arnold D, Kubicka S, Prasnikar N, Vogel A. Hofheinz RD, et al. Among authors: kubicka s. Oncol Res Treat. 2015;38(6):300-8. doi: 10.1159/000382067. Epub 2015 May 12. Oncol Res Treat. 2015. PMID: 26045027 Review.

Cite

Share

2

Cite

Share

[Palliative treatment for colorectal cancer].

Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Moehler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D. Hegewisch-Becker S, et al. Among authors: kubicka s. Onkologie. 2009;32 Suppl 2:13-6. doi: 10.1159/000213484. Epub 2009 Jun 22. Onkologie. 2009. PMID: 19546597 Review. German.

Cite

Share

3

Cite

Share

Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).

Hofheinz RD, Kubicka S, Wollert J, Arnold D, Hochhaus A. Hofheinz RD, et al. Among authors: kubicka s. Onkologie. 2006 Dec;29(12):563-7. doi: 10.1159/000096449. Epub 2006 Dec 11. Onkologie. 2006. PMID: 17202826 Clinical Trial.

Cite

Share

4

Cite

Share

Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.

Zender L, Kubicka S. Zender L, et al. Among authors: kubicka s. Onkologie. 2008 Oct;31(10):550-5. doi: 10.1159/000151586. Epub 2008 Sep 9. Onkologie. 2008. PMID: 18854656 Review.

Cite

Share

5

Cite

Share

Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.

Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Kirstein MM, et al. Among authors: kubicka s. Oncologist. 2014 Nov;19(11):1156-68. doi: 10.1634/theoncologist.2014-0032. Epub 2014 Oct 17. Oncologist. 2014. PMID: 25326159 Free PMC article.

Cite

Share

6

Cite

Share

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: kubicka s. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.

Cite

Share

7

Cite

Share

Low-toxicity treatment for colorectal cancer in elderly people.

Kubicka S. Kubicka S. Lancet Oncol. 2013 Oct;14(11):1031-1032. doi: 10.1016/S1470-2045(13)70426-1. Epub 2013 Sep 10. Lancet Oncol. 2013. PMID: 24028812 No abstract available.

Cite

Share

8

Cite

Share

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.

Rautenberg T, Siebert U, Arnold D, Bennouna J, Kubicka S, Walzer S, Ngoh C. Rautenberg T, et al. Among authors: kubicka s. J Med Econ. 2014 Feb;17(2):99-110. doi: 10.3111/13696998.2013.864973. Epub 2013 Dec 3. J Med Econ. 2014. PMID: 24215550

Cite

Share

9

Cite

Share

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geißler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie (AIO). Moehler M, et al. Among authors: kubicka s. Ann Oncol. 2011 Jun;22(6):1358-1366. doi: 10.1093/annonc/mdq591. Epub 2010 Nov 30. Ann Oncol. 2011. PMID: 21119032 Clinical Trial.

Cite

Share

10

Cite

Share

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U. Schmiegel W, et al. Among authors: kubicka s. Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4. Ann Oncol. 2013. PMID: 23463625 Clinical Trial.

Cite

Share